INT236877

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 16
Disease Relevance 16.43
Pain Relevance 0.56

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (BPHL) cellular amino acid metabolic process (BPHL)
BPHL (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 174 98.00 Very High Very High Very High
Onset of action 20 74.56 Quite High
agonist 5 57.40 Quite High
imagery 5 50.60 Quite High
headache 10 40.84 Quite Low
Central nervous system 9 40.80 Quite Low
visual analogue scale 12 5.00 Very Low Very Low Very Low
withdrawal 9 5.00 Very Low Very Low Very Low
Pain 7 5.00 Very Low Very Low Very Low
depression 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Benign Prostatic Hypertrophy 1326 100.00 Very High Very High Very High
Overactive Bladder 390 97.48 Very High Very High Very High
Hematuria 56 95.40 Very High Very High Very High
Diuresis 121 95.00 High High
Reprotox - General 1 267 94.84 High High
Disease 103 94.32 High High
Incontinence 38 94.16 High High
Disease Progression 34 93.20 High High
Lower Urinary Tract Symptoms 574 93.08 High High
Renal Insufficiency 25 91.68 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
They have also proven to be beneficial in the prevention of BPH progression, as measured by prostate volume, the risk of developing acute urinary retention, and the risk of having BPH-related surgery.3 The use of an alpha-adrenergic receptor antagonist and a 5-alpha-reductase inhibitor as combination therapy seeks to provide symptomatic relief while preventing progression of BPH and has been validated by the Medical Therapy of Prostate Symptoms (MTOPS) trial.4 Anti-cholinergic agents and phosphodiesterase-5 inhibitors have also recently shown efficacy in the management of LUTS.
Negative_regulation (prevention) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy, antagonist, overactive bladder and lower urinary tract symptoms
1) Confidence 0.32 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.31 Pain Relevance 0.13
They have also proven to be beneficial in the prevention of BPH progression, as measured by prostate volume, the risk of developing acute urinary retention, and the risk of having BPH-related surgery.3 The use of an alpha-adrenergic receptor antagonist and a 5-alpha-reductase inhibitor as combination therapy seeks to provide symptomatic relief while preventing progression of BPH and has been validated by the Medical Therapy of Prostate Symptoms (MTOPS) trial.4 Anti-cholinergic agents and phosphodiesterase-5 inhibitors have also recently shown efficacy in the management of LUTS.
Negative_regulation (preventing) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy, antagonist, overactive bladder and lower urinary tract symptoms
2) Confidence 0.32 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.16 Pain Relevance 0.12
These studies also confirmed the PLESS finding of decreased BPH progression in patients being treated with 5-alpha-reductase inhibitors.
Negative_regulation (decreased) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
3) Confidence 0.32 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.93 Pain Relevance 0
In the early 21st century, 5-alpha-reductase therapy is used to prevent progression of BPH, and is a viable alternative to alpha blockers or combination therapy for the treatment of symptoms.
Negative_regulation (prevent) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
4) Confidence 0.32 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.03 Pain Relevance 0.04
Symptoms can be treated with alpha adrenergic receptor antagonists, long-term 5-alpha-reductase inhibitor therapy, or combination therapy whereas only 5-alpha-reductase inhibitors (as mono-therapy or part of combination therapy) seem to prevent progression of BPH.
Negative_regulation (prevent) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy and antagonist
5) Confidence 0.32 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.99 Pain Relevance 0.05
-reductase reduces the clinical progression of BPH, an effect that is further enhanced by the addition of an ?
Negative_regulation (reduces) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
6) Confidence 0.21 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2684085 Disease Relevance 1.09 Pain Relevance 0.08
-reductase inhibitor finasteride has been shown to significantly reduce the overall risk of clinical progression of BPH compared with the use of either drug alone.
Negative_regulation (reduce) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
7) Confidence 0.21 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2684085 Disease Relevance 0.98 Pain Relevance 0.05
Compared with the placebo group, the risk of clinical progression of BPH, reported as rate per 100 person-years, was reduced by 39% in the doxazocin group (p < 0.001), by 34% in the finasteride group (p = 0.002), and by 66% in the combination therapy group (p < 0.001).
Negative_regulation (reduced) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
8) Confidence 0.21 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2684085 Disease Relevance 0.84 Pain Relevance 0.04
In conclusion, finasteride represents a cost-effective means of reducing BPH progression and its complications in men with enlarged prostates >30 cm3 while providing the additional benefits of decreased hematuria and prostate cancer rates.



Negative_regulation (reducing) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy, reprotox - general 1 and hematuria
9) Confidence 0.19 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710385 Disease Relevance 1.03 Pain Relevance 0
In comparison with the MTOPS study, men recruited into the CombAT study are deemed to be at higher risk of BPH progression, with baseline PV ?
Negative_regulation (risk) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
10) Confidence 0.18 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2440415 Disease Relevance 0.57 Pain Relevance 0
Indeed, PSA alone showed a sensitivity for predicting the progression of BPH comparable with the use of an algorithm and the five-variable model (encompassing the indices of serum PSA, symptom problems, peak urinary flow, urinary frequency ?
Negative_regulation (predicting) of Gene_expression (progression) of BPH associated with diuresis, benign prostatic hypertrophy and incontinence
11) Confidence 0.18 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2440415 Disease Relevance 0.95 Pain Relevance 0.03
Identifying men at risk of BPH progression
Negative_regulation (risk) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
12) Confidence 0.18 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2440415 Disease Relevance 0.67 Pain Relevance 0
BPH progression: definitions and prevalence
Negative_regulation (definitions) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
13) Confidence 0.18 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2440415 Disease Relevance 1.31 Pain Relevance 0
BPH progression: definitions and prevalence
Negative_regulation (prevalence) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
14) Confidence 0.18 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2440415 Disease Relevance 1.32 Pain Relevance 0
In men at risk for BPH progression events, the cumulative incidence of overall BPH clinical progression was significantly reduced 26% during treatment with alfuzosin compared with that during placebo treatment (16.3% versus 22.1% for placebo; p < 0.0001).
Negative_regulation (reduced) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
15) Confidence 0.16 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682383 Disease Relevance 0.87 Pain Relevance 0
1-blocker monotherapy (Lepor et al 1996; Debruyne et al 1998; Kirby et al 2003), a 5-year study of combination therapy with doxazosin and finasteride demonstrated a significantly reduced risk of overall BPH progression (ie, increase in AUA Symptom Index of ?
Negative_regulation (reduced) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
16) Confidence 0.16 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682383 Disease Relevance 1.39 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox